رجوع
نطاق اليوم
KWD 15.95
KWD 16.57
نطاق 52 أسبوعًا
KWD 9.24
KWD 19.00
حجم التداول
645,549
متوسط 50 يوم / 200 يوم
KWD 15.86
/
KWD 14.09
الإغلاق السابق
KWD 16.60
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (627 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -4.5 | 0.3 |
| P/B | 8.7 | 2.9 |
| ROE % | -121.5 | 3.7 |
| Net Margin % | — | 3.8 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | 0.1 | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 32.330
+96.4%
Low: KWD 28.000
High: KWD 37.000
ربحية السهم المستقبلية
-KWD 2.567
الإيرادات المقدّرة
62 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
KWD 3.082
KWD 2.716 – KWD 3.317
|
510 M | 2 |
| FY2029 |
KWD 1.962
KWD 1.729 – KWD 2.111
|
420 M | 2 |
| FY2028 |
KWD 0.450
-KWD 2.803 – KWD 7.861
|
300 M | 6 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 6,693 | KWD 16.081 | KWD 107,633 |
| Mar 6, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 31,250 | — | — |
| Feb 23, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 10,034 | KWD 15.567 | KWD 156,197 |
| Feb 21, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 46,500 | — | — |
| Feb 18, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 1,038 | KWD 15.000 | KWD 15,570 |
| Feb 18, 2026 |
Yea Christopher
CHIEF DEVELOPMENT OFFICER
|
sell | 1,109 | KWD 15.000 | KWD 16,635 |
| Feb 18, 2026 |
Audhya Paul K.
CHIEF MEDICAL OFFICER
|
sell | 1,163 | KWD 15.000 | KWD 17,445 |
| Feb 17, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 4,838 | — | — |
| Feb 17, 2026 |
Yea Christopher
CHIEF DEVELOPMENT OFFICER
|
other | 3,548 | — | — |
| Feb 17, 2026 |
Audhya Paul K.
CHIEF MEDICAL OFFICER
|
other | 4,838 | — | — |
| Feb 12, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 3,354 | KWD 15.700 | KWD 52,658 |
| Feb 11, 2026 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 14,240 | — | — |
| Jan 16, 2026 |
Audhya Paul K.
CHIEF MEDICAL OFFICER
|
grant | 100,000 | — | — |
| Jan 16, 2026 |
Sweeny Nicole
Chief Commercial Officer
|
grant | 100,000 | — | — |
| Jan 16, 2026 |
Arif Bilal
Chief Operations Officer
|
grant | 49,000 | — | — |
| Dec 8, 2025 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 7,294 | KWD 16.510 | KWD 120,424 |
| Dec 6, 2025 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
other | 31,250 | — | — |
| Nov 24, 2025 |
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
|
sell | 10,940 | KWD 13.451 | KWD 147,154 |
| Nov 24, 2025 |
Yea Christopher
CHIEF DEVELOPMENT OFFICER
|
sell | 4,331 | KWD 13.451 | KWD 58,256 |
| Nov 24, 2025 |
Piekos Brian
Chief Financial Officer
|
sell | 4,471 | KWD 13.451 | KWD 60,139 |
النقاط الرئيسية
Debt/Equity of 0.07 — conservative balance sheet
Negative free cash flow of -153.34M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-121.50%
ROIC-138.64%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
0.07
Current Ratio5.35
Interest Coverage-32.50
التقييم
P/E Ratio
-4.54
P/B Ratio8.72
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -183.44M |
| ROE | -121.50% | ROA | -73.15% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -153.34M |
| ROIC | -138.64% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.07 | Current Ratio | 5.35 |
| Interest Coverage | -32.50 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -4.54 | P/B Ratio | 8.72 |
| P/S Ratio | N/A | PEG Ratio | -0.51 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 831.99M | Enterprise Value | 739.65M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -183.44M | -126.64M | -92.91M | -82.34M | -46.24M |
| EPS (Diluted) | -3.69 | -3.44 | -3.33 | -3.36 | -2.33 |
| Gross Profit | 0.0 | -86.17M | 0.0 | 0.0 | -41.29M |
| Operating Income | -188.00M | -140.45M | -110.87M | -96.61M | -57.92M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 250.77M | 235.40M | 183.20M | 203.88M | 272.01M |
| Total Liabilities | 155.38M | 28.82M | 22.18M | 18.79M | 14.82M |
| Shareholders' Equity | 95.39M | 206.58M | 161.03M | 185.09M | 257.19M |
| Total Debt | 6.31M | 7.32M | 8.23M | 8.19M | 5.91M |
| Cash & Equivalents | 98.64M | 31.79M | 56.24M | 30.73M | 50.59M |
| Current Assets | 241.69M | 225.69M | 172.33M | 193.65M | 264.26M |
| Current Liabilities | 45.17M | 22.81M | 15.03M | 11.58M | 9.77M |